14-Sep-2020 | Market Research Store
The University of Illinois Chicago researchers have developed a new breast cancer drug that can hinder the progression of the disease without causing any toxic effects. The drug is currently in the phase 1 clinical trial. This newly developed drug is a savior for women whose cancer has stopped reacting to any kind of hormone therapy. In the U.S., there are 1 in 8 women who have breast cancer and there are many types of breast cancer which are grouped into estrogen receptor-positive (ER-positive). The receptors of the cancer cells are sensitive as well as react to the hormone estrogen.
Estrogen basically powers cancer growth in case of ER-positive breast cancer and thus, blocking this hormone production will help avoid the interference of this hormone with the cancer cells. This type of hormone therapy helps destroy cancer cells but they tend to make the individual resistant to the treatment, leaving them with few treatments other than chemotherapy that is known to have toxic side effects. The development of the new drug called TTC-352, a discerning human estrogen receptor partial agonist, is known to cause tumor regression with low risk of uterine cancer. The drug was effective in helping reduce the progression of the disease without causing any side effect.
This drug is a tolerable alternative to chemotherapy that is not only safe but also helped inhibit the growth for a significant amount of time. The new finding published in the journal Breast Cancer Research and Treatment is believed to set a new therapeutic breakthrough in cancer research in the coming years. The dose of this drug has been set well within the therapeutic standard that is generally given to treat breast cancer. This new alternative for chemotherapy is the best treatment the breast cancer patients could have asked for.
Market Research Store has published a report on global breast cancer therapeutics drugs market. The report on breast cancer therapeutics drugs market provides the necessary market analysis and strategic data that can help the others wanting to invest in the industry to take the right decisions.